Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AACR, aggressive, Aid, announced, Asia, AstraZeneca, ATM, blockade, blockading, CAA, Cannon, capable, carryback, carryforward, clearer, constantly, contact, COVID, crizotinib, Crosstalk, dacomitinib, decade, disinfecting, distancing, economy, embedded, endocrine, ErbB, Faslodex, FBR, fighting, frequently, fulvestrant, halted, home, HR, incentivizing, Inline, Interactive, Jonsson, labor, leader, light, magnified, magnitude, ordinary, outbreak, pandemic, postponed, proactive, promulgated, quarantine, RAS, RECIST, Relief, remote, Riley, Sarah, site, strain, suspending, tasked, temperature, TRA, turnover, twelve, UCLA, undetectable, unmet, untangle, variance, Vizimpro, women, workforce, Wuhan, Xalkori
Filing tables
Filing exhibits
- 10-K Annual report
- 10.15 Amendment No. 1 Clinical Trial Agreement for FB-12 Phase II Study
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Under Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 Certification Under Section 302 of the Sarbanes-oxley Act of 2002
- 32.1 Certification Pursuant to 18 U.s.c. Section 1350, As Adopted
- 32.2 Certification Pursuant to 18 U.s.c. Section 1350, As Adopted
- Download Excel data file
- View Excel data file
Related press release
Associated CELC transcripts
CELC similar filings
Filing view
External links